175 related articles for article (PubMed ID: 16176336)
1. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
Sébille V; Bellissant E
Fundam Clin Pharmacol; 2005 Oct; 19(5):569-78. PubMed ID: 16176336
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
Sebille V; Bellissant E
Clin Sci (Lond); 2000 May; 98(5):569-78. PubMed ID: 10781388
[TBL] [Abstract][Full Text] [Related]
3. Sequential boundaries approach in clinical trials with unequal allocation ratios.
Jafari P; Ayatollahi SM; Behboodian J
BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
[TBL] [Abstract][Full Text] [Related]
4. Sequential analysis of latent variables using mixed-effect latent variable models: Impact of non-informative and informative missing data.
Sébille V; Hardouin JB; Mesbah M
Stat Med; 2007 Nov; 26(27):4889-904. PubMed ID: 17576119
[TBL] [Abstract][Full Text] [Related]
5. An algorithm for the design of group sequential triangular tests for single-arm clinical trials with a binary endpoint.
McWilliams TP
Stat Med; 2010 Nov; 29(27):2794-801. PubMed ID: 20860065
[TBL] [Abstract][Full Text] [Related]
6. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
7. [Design and analysis of phase II trials in oncology with a group sequential method, the triangular test].
Bellissant E; Bénichou J; Chastang C
Therapie; 1991; 46(1):21-7. PubMed ID: 2020920
[TBL] [Abstract][Full Text] [Related]
8. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
9. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
10. Information-based monitoring of clinical trials.
Tsiatis AA
Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
[TBL] [Abstract][Full Text] [Related]
11. A note on P-values under group sequential testing and nonproportional hazards.
Gillen DL; Emerson SS
Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
[TBL] [Abstract][Full Text] [Related]
12. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
13. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
14. Symmetric group sequential test designs.
Emerson SS; Fleming TR
Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
[TBL] [Abstract][Full Text] [Related]
15. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
Goldman AI; Hannan PJ
Stat Med; 2001 Jun; 20(11):1575-89. PubMed ID: 11391689
[TBL] [Abstract][Full Text] [Related]
16. Sequential designs for phase III clinical trials incorporating treatment selection.
Stallard N; Todd S
Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
[TBL] [Abstract][Full Text] [Related]
17. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
18. Designs for efficient clinical trials.
Simon R
Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
[TBL] [Abstract][Full Text] [Related]
19. [Roaming through methodology. XXXIII. Ethics of sample size estimation: less subjects needed for a one-sided than for a two-sided statistical investigation].
Knottnerus JA; Bouter LM
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1051-4. PubMed ID: 11414165
[TBL] [Abstract][Full Text] [Related]
20. Optimal two-stage designs for clinical trials based on safety and efficacy.
Thall PF; Cheng SC
Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
